News on the Role of Antidepressants in and for COVID-19 and Long COVID [0.03%]
关于抗抑郁药在新冠肺炎和长新冠中的作用的报道
Udo Bonnet,Georg Juckel
Udo Bonnet
Monitoring Anesthetic Depth Using the Patient State Index in Electroconvulsive Therapy Improves Seizure Quality [0.03%]
使用患者状态指数监测电休克治疗中的麻醉深度可提高惊厥质量
Oscar Alcoverro-Fortuny,Ferran Viñas Usan,Carmen E Sanabria et al.
Oscar Alcoverro-Fortuny et al.
Objectives: The determination of anesthetic depth has been used to assess the optimal moment for applying electrical stimuli in electroconvulsive therapy (ECT), as some of the anesthetics used can reduce its effectiveness...
Correction: Electroconvulsive Therapy Versus Aripiprazole Addition to Clozapine in Patients with Clozapine-Resistant Symptoms (EMECLO): A Protocol of a Single-Blind, Multicenter, Randomized-Controlled Feasibility Trial [0.03%]
纠正：氯氮平抵抗症状患者中电抽搐治疗与艾司西酞普兰联合氯氮平治疗的比较（EMECLO）：一项单盲多中心随机对照可行性试验方案
Manouk den Toom,Laura Blanken,Inge Horn et al.
Manouk den Toom et al.
Published Erratum
Pharmacopsychiatry. 2024 Nov;57(6):e1. DOI:10.1055/a-2406-6396 2024
Association Study Between DRD2, DRD3 Genetic Polymorphisms and Adverse Reactions in Chinese Patients on Amisulpride Treatment [0.03%]
中国 amisulpride 治疗患者多巴胺 D2、D3 受体基因多态性与不良反应的关联研究
Kankan Qu,Yanan He,Zhongdong Zhang et al.
Kankan Qu et al.
Objective: To determine if the cardiac function and "endocrinium" of Chinese patients are associated with dopamine D2 (DRD2) (rs6276) and DRD3 (rs6280, rs963468) genetic polymorphisms when treated with amisulpride. ...
Electroconvulsive Therapy Versus Aripiprazole Addition to Clozapine in Patients with Clozapine-Resistant Symptoms (EMECLO): A Protocol of a Single-Blind, Multicenter, Randomized-Controlled Feasibility Trial [0.03%]
电抽搐治疗与喹硫平联合治疗氯氮平抵抗症状的患者：单盲、多中心、随机对照可行性试验方案（EMECLO）
Manouk den Toom,Laura Blanken,Inge Horn et al.
Manouk den Toom et al.
Background: Currently, guidance on the most effective treatment for patients with clozapine-resistant schizophrenia-spectrum disorders (SSD) is lacking. While augmentation strategies to clozapine with aripiprazole and ele...
Increased Odds of Cognitive Impairment in Adults with Depressive Symptoms and Antidepressant Use [0.03%]
抑郁症状和抗抑郁药使用与成人认知障碍风险增加有关
Shakila Meshkat,Michelle Wu,Vanessa K Tassone et al.
Shakila Meshkat et al.
Introduction: The relationship between antidepressant use and class with cognition in depression is unclear. This study aimed to evaluate the association of cognition with depressive symptoms and antidepressant use (class...
Twenty-Three Years of Declining Lithium Use: Analysis of a Pharmacoepidemiological Dataset from German-Speaking Countries [0.03%]
德国说德语国家药物流行病学数据集中锂剂使用量下降23年分析研究
Waldemar Greil,Mateo de Bardeci,Nadja Nievergelt et al.
Waldemar Greil et al.
Introduction: Pharmacoepidemiological data suggest that lithium prescriptions for bipolar disorder are gradually decreasing, with less attention having been paid to other indications. ...
Precision Psychiatry Approach to Treat Depression and Anxiety Targeting the Stress Hormone System - V1b-antagonists as a Case in Point [0.03%]
精准精神病学治疗抑郁症和焦虑症方法——以针对压力激素系统的V1b受体拮抗剂为例
Florian Holsboer,Marcus Ising
Florian Holsboer
The future of depression pharmacotherapy lies in a precision medicine approach that recognizes that depression is a disease where different causalities drive symptoms. That approach calls for a departure from current diagnostic categories, ...
SARS-CoV-2-Infection in People Addicted to Illegal Drugs - Is There a Protective Effect of Opioid Maintenance Treatment? [0.03%]
非法药物成瘾者感染SARS-CoV-2的情况——阿片类维持治疗有保护作用吗？
Simon Kurzhals,Martin Schäfer,Udo Bonnet et al.
Simon Kurzhals et al.
Introduction: People addicted to illegal drugs were discussed as a risk group for SARS-CoV-2 infections, with increased susceptibility and a severe course of infection. ...
Recreational Cannabis Legalization: No Contribution to Rising Prescription Stimulants in the USA [0.03%]
娱乐性大麻合法化不会导致美国处方兴奋剂使用增加
Garrett D Alexander,Luke R Cavanah,Jessica L Goldhirsh et al.
Garrett D Alexander et al.
Introduction: There have been substantial increases in the use of Schedule II stimulants in the United States. Schedule II stimulants are the gold standard treatment for attention-deficit hyperactivity disorder (ADHD), bu...